大行每日評級 | 瑞信看好線上醫療健康平臺,首選京東健康
今日看點
1.瑞信指,內地線上醫療高增長的情況會持續,主因去年疫情帶動線上醫療的增長。科技創新將是未來增長的基礎,預期臨牀決策支持系統將於短期內可以大規模商用。首選京東健康(06618),其次是阿裏健康(00241),最後是平安好醫生(01833),均首予跑贏大市評級,目標價分別爲161港元、30港元及115港元。
2.花旗重申對小米集團-W(01810)的買入評級,目標價30港元。該行認爲小米被移出黑名單還可能增加公司自6月21日起被重新納入富時羅素指數的機會。相信市場對智能手機市場疲軟的擔心是過度的,預計小米能夠在二季度實現強勁增長,因市場份額擴張。
【小米集團支持20倍槓桿日內交易】
3.Oppenheimer維持對Moderna(MRNA)“跑贏大盤”評級,目標價206美元,對於潛在35%的上漲空間。該行稱,公司員工數增加了2倍,並繼續按照行業戰略向高端製造和智能領域入大量的資源,業績有望在未來得到兌現。公司幾乎不會受到專利版權帶來的利空影響。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.